A RANDOMIZED STUDY TO COMPARE THE EFFECT OF THE LUTEINIZING-HORMONE-RELEASING HORMONE (LHRH) ANALOG GOSERELIN WITH OR WITHOUT TAMOXIFEN IN PREMENOPAUSAL AND PERIMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER

被引：76

作者：

JONAT, W

KAUFMANN, M

BLAMEY, RW

HOWELL, A

COLLINS, JP

COATES, A

EIERMANN, W

JANICKE, F

NJORDENSKOLD, B

FORBES, JF

KOLVENBAG, GJCM

机构：

[1] UNIV HEIDELBERG, HEIDELBERG, GERMANY

[2] CITY HOSP, SURG UNIT, NOTTINGHAM, ENGLAND

[3] CHRISTIE HOSP & HOLT RADIUM INST, MANCHESTER, LANCS, ENGLAND

[4] ROTEN KREUZ, FRAUENKLIN, MUNICH, GERMANY

[5] TECH UNIV MUNICH, FRAUENKLIN, MUNICH, GERMANY

[6] LINKOPING UNIV, DEPT ONCOL, LINKOPING, SWEDEN

[7] NEWCASTLE MATER HOSP, OPERAT OFF, ANZ BREAST CANC TRIALS GRP, WARATAH, NSW, AUSTRALIA

[8] ZENECA PHARMACEUT, MACCLESFIELD, CHESHIRE, ENGLAND

来源：

EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷 / 02期

关键词：

BREAST CANCER; GOSERELIN; RANDOMIZED TRIAL; TAMOXIFEN; ENDOCRINE THERAPY;

D O I：

10.1016/0959-8049(94)00415-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The use of goserelin with or without tamoxifen was investigated in a randomised multicentre study involving 318 pre- and perimenopausal advanced breast cancer patients. With a median follow-up of 93 weeks, 31% of goserelin-treated patients had objective responses (UICC criteria) compared with 38% of goserelin plus tamoxifen-treated patients (P = 0.24). There was a modest benefit in favour of combination therapy in time to progression (P = 0.03) but not in survival (P = 0.25). Median follow-up for survival was 117.5 weeks. Median times for disease progression and survival were 23 and 127 weeks in the goserelin alone group and 28 and 140 weeks in the combination group, respectively. In 115 patients with skeletal metastases only, significant differences in favour of combination therapy were seen in response rate, time to progression and survival. Both treatments were well tolerated and no additional safety issues were associated with combination therapy.

引用

页码：137 / 142

页数：6

共 20 条

[1]

Beatson G., 1896, LANCET, V148, P162, DOI DOI 10.1016/S0140-6736(01)72384-7

[2]

Beatson G.T., 1896, LANCET, V15, P153, DOI DOI 10.1016/S0140-6736(01)72307-0

[3] GOSERELIN DEPOT IN THE TREATMENT OF PREMENOPAUSAL ADVANCED BREAST-CANCER [J].

BLAMEY, RW ;

JONAT, W ;

KAUFMANN, M ;

BIANCO, AR ;

NAMER, M .

EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) :810-814

[4]

BUCHANAN RB, 1986, J CLIN ONCOL, V4, P1236

[5]

CONTE CC, 1989, CANCER, V64, P150, DOI 10.1002/1097-0142(19890701)64:1<150::AID-CNCR2820640125>3.0.CO

[6]

2-N

[7]

DIXON AR, 1990, 1ST NOTT INT BREAST, V2, P41

[8]

ERIKSEN EF, 1987, INT S OSTEOPOROSIS A

[9]

ERNST M, 1987, OSTEOPRESS, V1, P198

[10] ASSESSMENT OF RESPONSE TO THERAPY IN ADVANCED BREAST-CANCER - PROJECT OF PROGRAM ON CLINICAL ONCOLOGY OF "INTERNATIONAL-UNION-AGAINST-CANCER, GENEVA, SWITZERLAND [J].

HAYWARD, JL ;

CARBONE, PP ;

HEUSON, JC ;

KUMAOKA, S ;

SEGALOFF, A ;

RUBENS, RD .

EUROPEAN JOURNAL OF CANCER, 1977, 13 (01) :89-94

← 1 2 →